GnRH antagonist
Ganirelix
Answer
Ganirelix is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 108 registered trials, 11 of them running. Brand names on the FDA label register: Ganirelix Acetate and Fyremadel.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
108 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 12 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 63 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
CHANGE ALERTS
Get an email when this changes
One email when the status of Ganirelix changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 108 trials
| NCT07732348 | Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: not yet recruiting participants · register updated 2026-09-30 |
|---|---|
| NCT06745466 | Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women currently recruiting participants · register updated 2026-07-02 |
| 2023-508769-33-00 | Protocol with Progestin-primed Ovarian Stimulation (PPOS) in conventional treatment from the start of stimulation vs protocol with no status recorded · register updated 2026-05-25 |
| NCT06877429 | Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulat not yet recruiting participants · register updated 2026-05-07 |
| NCT04983173 | INTEnsity of ovariaN Stimulation and Embryo Quality completed · register updated 2026-04-14 |
| NCT05954962 | Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. completed · register updated 2026-03-27 |
| NCT07409493 | IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols currently recruiting participants · register updated 2026-02-13 |
| NCT06175832 | PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study currently recruiting participants · register updated 2025-12-26 |
| NCT05847283 | DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT currently recruiting participants · register updated 2025-12-10 |
| NCT04166825 | Ovarian Hyperstimulation and Fibrin Clot Properties. currently recruiting participants · register updated 2025-12-05 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.